Next earnings date: 29 Sep 2025
Renalytix Plc – LSE:RENX.L
Renalytix stock price today
Renalytix stock price monthly change
Renalytix stock price quarterly change
Renalytix stock price yearly change
Renalytix key metrics
Market Cap | 34.77M |
Enterprise value | 6.75B |
P/E | -1.34 |
EV/Sales | 1955.13 |
EV/EBITDA | -156.72 |
Price/Sales | 18.82 |
Price/Book | 2.57 |
PEG ratio | 0.05 |
EPS | -0.44 |
Revenue | 2.41M |
EBITDA | -33.02M |
Income | -42.49M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -1292.45% |
Oper. margin | -1574.8% |
Gross margin | 23.23% |
EBIT margin | -1574.8% |
EBITDA margin | -1370.21% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRenalytix stock price history
Renalytix stock forecast
Renalytix financial statements
| Mar 2023 | 724K | -12.10M | -1672.1% |
|---|---|---|---|
| Jun 2023 | 518K | -11.10M | -2143.63% |
| Sep 2023 | 459K | -10.15M | -2212.2% |
| Dec 2023 | 709K | -9.13M | -1288.01% |
| 2025 | 46.24M | -15.54M | -33.61% |
|---|---|---|---|
| 2026 | 56.53M | -8.33M | -14.74% |
| 2026 | 104.83M | 21.41M | 20.42% |
| 2027 | 106.06M | 18.30M | 17.26% |
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 38713000 | 19.87M | 51.33% |
|---|---|---|---|
| Dec 2022 | 30660000 | 21.77M | 71.02% |
| Sep 2023 | 19540000 | 21.03M | 107.63% |
| Dec 2023 | 21874000 | 19.20M | 87.81% |
| Mar 2023 | -10.10M | 5K | 18.01M |
|---|---|---|---|
| Jun 2023 | -8.63M | 59K | -98K |
| Sep 2023 | -9.50M | 0 | -1.06M |
| Dec 2023 | -7.84M | 0 | -588K |
Renalytix alternative data
| Aug 2023 | 102 |
|---|---|
| Sep 2023 | 102 |
| Oct 2023 | 102 |
| Nov 2023 | 102 |
| Dec 2023 | 102 |
| Jan 2024 | 102 |
| Feb 2024 | 102 |
| Mar 2024 | 102 |
| Apr 2024 | 102 |
| May 2024 | 102 |
| Jun 2024 | 102 |
| Jul 2024 | 102 |
Renalytix other data
| Insider | Compensation |
|---|---|
Mr. James R. McCullough M.B.A. (1968) Chief Executive Officer & Executive Director | $1,130,000 |
Mr. Fergus Fleming (1967) Chief Technology Officer & Executive Director | $587,000 |
-
What's the price of Renalytix stock today?
One share of Renalytix stock can currently be purchased for approximately $620.
-
When is Renalytix's next earnings date?
Renalytix Plc is estimated to report earnings on Monday, 29 Sep 2025.
-
Does Renalytix pay dividends?
No, Renalytix does not pay dividends.
-
How much money does Renalytix make?
Renalytix has a market capitalization of 34.77M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 32.74% to 2.29M US dollars.
-
What is Renalytix's stock symbol?
Renalytix Plc is traded on the LSE under the ticker symbol "RENX.L".
-
What is Renalytix's primary industry?
Company operates in the Healthcare sector and Medical - Healthcare Information Services industry.
-
How do i buy shares of Renalytix?
Shares of Renalytix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Renalytix's key executives?
Renalytix's management team includes the following people:
- Mr. James R. McCullough M.B.A. Chief Executive Officer & Executive Director(age: 57, pay: $1,130,000)
- Mr. Fergus Fleming Chief Technology Officer & Executive Director(age: 58, pay: $587,000)
-
How many employees does Renalytix have?
As Jul 2024, Renalytix employs 102 workers.
-
When Renalytix went public?
Renalytix Plc is publicly traded company for more then 6 years since IPO on 6 Nov 2018.
-
What is Renalytix's official website?
The official website for Renalytix is renalytix.com.
-
Where are Renalytix's headquarters?
Renalytix is headquartered at 1460 Broadway, New York, NY.
-
How can i contact Renalytix?
Renalytix's mailing address is 1460 Broadway, New York, NY and company can be reached via phone at +64 6 397 3970.
Renalytix company profile:
Renalytix Plc
renalytix.comLSE
102
Medical - Healthcare Information Services
Healthcare
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
New York, NY 10036
:
ISIN: GB00BYWL4Y04
CUSIP: G7489R108
